{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:07:03Z","timestamp":1795021623461,"version":"4.10.1"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ajo.2023.12.001","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T02:39:14Z","timestamp":1703299154000},"page":"152-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Reactivation After Teprotumumab Treatment for Active Thyroid Eye Disease"],"prefix":"10.1016","volume":"263","author":[{"given":"Catherine J.","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0161-6216","authenticated-orcid":false,"given":"Nicole P.","family":"Rebollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keegan B.","family":"Mechels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.ajo.2023.12.001_bib0001","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajo.2023.12.001_bib0002","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ajo.2023.12.001_bib0003","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.ajo.2023.12.001_bib0004","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-23-0043","article-title":"Teprotumumab in thyroid eye disease: wonder drug or great divider?","volume":"12","author":"Perros","year":"2023","journal-title":"Eur Thyroid J"},{"issue":"6","key":"10.1016\/j.ajo.2023.12.001_bib0005","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/IOP.0000000000001959","article-title":"Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population","volume":"37","author":"Diniz","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ajo.2023.12.001_bib0006","series-title":"Ophthalmic Plast Reconstr Surg","article-title":"Proptosis regression after teprotumumab treatment for thyroid eye disease","author":"Rosenblatt","year":"2023"},{"issue":"1","key":"10.1016\/j.ajo.2023.12.001_bib0007","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.ajo.2023.12.001_bib0008","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X Study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2023.12.001_bib0009","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/IOP.0000000000000371","article-title":"Recurrent thyroid eye disease","volume":"31","author":"Patel","year":"2015","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ajo.2023.12.001_bib0010","unstructured":"Horizon Therapeutics USA, Inc. TEPEZZA\u00ae (Teprotumumab-trbw) Post-Marketing Requirement Study. ClinicalTrials.gov identifier: NCT05002998. Updated November, 7, 2023. Accessed November 17, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05002998."},{"issue":"2","key":"10.1016\/j.ajo.2023.12.001_bib0011","first-page":"150","article-title":"Outcomes of patients with thyroid eye disease partially treated with teprotumumab","volume":"39","author":"Ho","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939423005044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939423005044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:59:42Z","timestamp":1731200382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939423005044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":11,"alternative-id":["S0002939423005044"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2023.12.001","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reactivation After Teprotumumab Treatment for Active Thyroid Eye Disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2023.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}